| Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
- Language: English
- [J Neurochem] 2021 Sep; Vol. 158 (6), pp. 1334-1344. <i>Date of Electronic Publication: </i>2021 Jan 07.
- MeSH Terms: Brain / *drug effects ; Brain / *metabolism ; Cholinergic Antagonists / *adverse effects ; Tardive Dyskinesia / *chemically induced ; Tardive Dyskinesia / *metabolism ; Animals ; Brain / pathology ; Cholinergic Neurons / drug effects ; Cholinergic Neurons / metabolism ; Cholinergic Neurons / pathology ; Humans ; Tardive Dyskinesia / pathology
- References: Aghourian, M., Legault-Denis, C., Soucy, J. P., Rosa-Neto, P., Gauthier, S., Kostikov, A., Gravel, P., & Bedard, M. A. (2017). Quantification of brain cholinergic denervation in Alzheimer’s disease using PET imaging with [18F]-FEOBV. Molecular Psychiatry, 22, 1531-1538. ; American Geriatrics Society Beers Criteria® Update Expert Panel. (2019). American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics Society, 67, 674-694. ; Bertuzzi, M., & Ampatzis, K. (2018). Spinal cholinergic interneurons differentially control motoneuron excitability and alter the locomotor network operational range. Scientific Reports, 8, 1-10. ; Binning, W., Hogan-Cann, A. E., Sakae, D. Y., Maksoud, M., Ostapchenko, V., Al-Onaizi, M., Matovic, S., Lu, W. Y., Prado, M. A., Inoue, W., & Prado, V. F. (2020) Chronic hM3Dq signaling in microglia ameliorates neuroinflammation in male mice. bioRxiv, 88, 791-801. ; Bohnen, N. I., Kaufer, D. I., Ivanco, L. S., Lopresti, B., Koeppe, R. A., Davis, J. G., Mathis, C. A., Moore, R. Y., & DeKosky, S. T. (2020). Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Archives of Neurology, 60, 1745-1748. ; Boustani, M., Campbell, N., Munger, S., Maidment, I., & Fox, C. (2008). Impact of anticholinergics on the aging brain: A review and practical application. ; Braak, H., Del Tredici, K., Rüb, U., De Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of Aging, 24, 197-211. ; Brichta, L., Greengard, P., & Flajolet, M. (2013) Advances in the pharmacological treatment of Parkinson’s disease: Targeting neurotransmitter systems. Trends in Neurosciences, 36, 543-554. ; Campanari, M. L., García-Ayllón, M. S., Ciura, S., Sáez-Valero, J., & Kabashi, E. (2016). Neuromuscular junction impairment in amyotrophic lateral sclerosis: Reassessing the role of acetylcholinesterase. Frontiers in Molecular Neuroscience, 9, 160. ; Carnahan, R. M., Lund, B. C., Perry, P. J., Pollock, B. G., & Gulp, K. R. (2006). The anticholinergic drug scale as a measure of drug-related anticholinergic burden: Associations with serum anticholinergic activity. Journal of Clinical Pharmacology, 46, 1481-1486. ; Carrière, I., Fourrier-Reglat, A., Dartigues, J. F., Rouaud, O., Pasquier, F., Ritchie, K., & Ancelin, M. L. (2009). Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: The 3-city study. Archives of Internal Medicine, 169, 1317-1324. ; Cavedo, E., Lista, S., Houot, M., Vergallo, A., Grothe, M. J., Teipel, S., Zetterberg, H., Blennow, K., Habert, M. O., Potier, M. C., & Dubois, B. (2020). Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. Neurology, 94, e30-e41. ; Chew, M. L., Mulsant, B. H., Pollock, B. G., Lehman, M. E., Greenspan, A., Mahmoud, R. A., Kirshner, M. A., Sorisio, D. A., Bies, R. R., & Gharabawi, G. (2008). Anticholinergic activity of 107 medications commonly used by older adults. Journal of the American Geriatrics Society, 56, 1333-1341. ; Colovic, M. B., Krstic, D. Z., Lazarevic-Pasti, T. D., Bondzic, A. M., & Vasic, V. M. (2013). Acetylcholinesterase inhibitors: Pharmacology and toxicology. Current Neuropharmacology, 11, 315-335. ; Coupland, C. A. C., Hill, T., Dening, T., Morriss, R., Moore, M., & Hippisley-Cox, J. (2019). Anticholinergic drug exposure and the risk of dementia: A nested case-control study. JAMA Internal Medicine, 179, 1084-1093. ; Cuenca-López, M. D., Brea, D., Segura, T., Galindo, M. F., Antón-Martínez, D., Agulla, J., Castillo, J., & Jordán, J. (2010). Inflammation as a therapeutic agent in cerebral infarction: Cellular inflammatory response and inflammatory mediators. Revista De Neurologia, 50, 349-359. ; Davis, A. A., Fritz, J. J., Wess, J., Lah, J. J., & Levey, A. I. (2010). Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo. Journal of Neuroscience, 30, 4190-4196. ; Durán, C. E., Azermai, M., & Stichele, R. H. V. (2013) Systematic review of anticholinergic risk scales in older adults. European Journal of Clinical Pharmacology, 69, 1485-1496. ; Eglen, R. M. (2006) Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. Autonomic and Autacoid Pharmacology, 26, 219-233. ; Eglen, R. M. (2012) Overview of muscarinic receptor subtypes. ; Evans, L. D., Wassmer, T., Fraser, G., Smith, J., Perkinton, M., Billinton, A., & Livesey, F. J. (2018). Extracellular monomeric and aggregated tau efficiently enter human neurons through overlapping but distinct pathways. Cell Reports, 22, 3612-3624. https://doi.org/10.1016/j.celrep.2018.03.021. ; Fischer, L. R., Culver, D. G., Tennant, P., Davis, A. A., Wang, M., Castellano-Sanchez, A., Khan, J., Polak, M. A., & Glass, J. D. (2004). Amyotrophic lateral sclerosis is a distal axonopathy: Evidence in mice and man. Experimental Neurology, 185, 232-240. https://doi.org/10.1016/j.expneurol.2003.10.004. ; Fisher, A., Bezprozvanny, I., Wu, L., Ryskamp, D. A., Bar-Ner, N., Natan, N., Brandeis, R., Elkon, H., Nahum, V., Gershonov, E., LaFerla, F. M., & Medeiros, R. (2016) AF710B, a novel M1/σ1 agonist with therapeutic efficacy in animal models of Alzheimer’s disease. Neurodegenerative Diseases, 16(1-2), 95-110. https://doi.org/10.1159/000440864. ; Friedman, A., Kaufer, D., Shemer, J., Hendler, I., Soreq, H., & Tur-Kaspa, I. (1996). Pyridostigmine brain penetration under stress enhances neuronal excitability and induces early immediate transcriptional response. Nature Medicine, 2, 1382-1385. ; Gamble, D. T., Clark, A. B., Luben, R. N., Wareham, N. J., Khaw, K. T., & Myint, P. K. (2018). Baseline anticholinergic burden from medications predicts incident fatal and non-fatal stroke in the EPIC-Norfolk general population. International Journal of Epidemiology, 47, 625-633. ; Gericke, A., Sniatecki, J. J., Mayer, V. G. A., Goloborodko, E., Patzak, A., Wess, J., & Pfeiffer, N. (2011). Role of m1, m3, and m5 muscarinic acetylcholine receptors in cholinergic dilation of small arteries studied with gene-targeted mice. American Journal of Physiology-Heart and Circulatory Physiology, 300, H1602-H1608. ; Gerretsen, P., & Pollock, B. G. (2011). Drugs with anticholinergic properties: A current perspective on use and safety. Expert Opinion on Drug Safety, 10, 751-765. ; Gray, S. L., Anderson, M. L., Dublin, S., Hanlon, J. T., Hubbard, R., Walker, R., Yu, O., Crane, P. K., & Larson, E. B. (2015). Cumulative use of strong anticholinergics and incident dementia: A prospective cohort study. JAMA Internal Medicine, 175, 401-407. ; Kaltsatou, A., Fotiou, D., Tsiptsios, D., & Orologas, A. (2015). Cognitive impairment as a central cholinergic deficit in patients with Myasthenia Gravis. BBA Clinical, 3, 299-303. https://doi.org/10.1016/j.bbacli.2015.04.003. ; Kolisnyk, B., Al-Onaizi, M., Soreq, L., Barbash, S., Bekenstein, U., Haberman, N., Hanin, G., Kish, M. T., Souza da Silva, J., Fahnestock, M., & Ule, J. (2017). Cholinergic surveillance over hippocampal RNA metabolism and Alzheimer’s-like pathology. Cerebral Cortex, 27, 3553-3567. ; Kuhl, D. E., Koeppe, R. A., Minoshima, S., Snyder, S. E., Ficaro, E. P., Foster, N. L., Frey, K. A., & Kilbourn, M. R. (1999). In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s disease. Neurology, 52, 691-699. https://doi.org/10.1212/WNL.52.4.691. ; Lange, K. W., Wells, F. R., Jenner, P., & Marsden, C. D. (1993). Altered muscarinic and nicotinic receptor densities in cortical and subcortical brain regions in Parkinson’s disease. Journal of Neurochemistry, 60, 197-203. https://doi.org/10.1111/j.1471-4159.1993.tb05838.x. ; Langmead, C. J., Watson, J., & Reavill, C. (2008). Muscarinic acetylcholine receptors as CNS drug targets. Pharmacology & Therapeutics, 117(2), 232-243. https://doi.org/10.1016/j.pharmthera.2007.09.009. ; Lindholm, D., da Penha Berzaghi, M., Cooper, J., Thoenen, H., & Castrén, E. (1994) Brain-derived neurotrophic factor and neurotrophin-4 increase neurotrophin-3 expression in the rat hippocampus. International Journal of Developmental Neuroscience, 12, 745-751. ; Morozova, V., Cohen, L. S., Makki, A.-E.-H., Shur, A., Pilar, G., Idrissi, A., & El, A. A. D. (2019). Normal and pathological tau uptake mediated by M1/M3 muscarinic receptors promotes opposite neuronal changes. Frontiers in Cellular Neuroscience, 13, 403. https://doi.org/10.3389/fncel.2019.00403. ; Medeiros, R., Kitazawa, M., Caccamo, A., Baglietto-Vargas, D., Estrada-Hernandez, T., Cribbs, D. H., Fisher, A., & Laferla, F. M. (2011). Loss of muscarinic M1 receptor exacerbates Alzheimer’s disease-like pathology and cognitive decline. American Journal of Pathology, 179, 980-991. ; Muir, J. L. (1997). Acetylcholine, aging, and Alzheimer’s disease. Pharmacology, Biochemistry and Behavior, 56, 687-696. ; Müller, M. L. T. M., & Bohnen, N. I. (2013). Cholinergic dysfunction in parkinson’s disease. Current Neurology and Neuroscience Reports, 13, 377. ; Nagao, M., Misawa, H., Kato, S., & Hirai, S. (1998). Loss of cholinergic synapses on the spinal motor neurons of amyotrophic lateral sclerosis. Journal of Neuropathology and Experimental Neurology, 57, 329-333. ; Newman, E. L., Gupta, K., Climer, J. R., Monaghan, C. K., & Hasselmo, M. E. (2012) Cholinergic modulation of cognitive processing: insights drawn from computational models. Frontiers in Behavioral Neuroscience, 6, 24. https://doi.org/10.3389/fnbeh.2012.00024. ; Oda, Y., Imai, S., Nakanishi, I., Ichikawa, T., & Deguchi, T. (1995). Immunohistochemical study on choline acetyltransferase in the spinal cord of patients with amyotrophic lateral sclerosis. Pathology International, 45, 933-939. ; Prado, V. F., Janickova, H., Al-Onaizi, M. A., & Prado, M. A. M. (2017). Cholinergic circuits in cognitive flexibility. Elsevier Ltd. ; Prado, V. F., Kolisnyk, B., Gros, R., & Prado, M. A. M. (2013). Regulation of cholinergic activity by the vesicular acetylcholine transporter Neurobiology View project Neuromuscular alterations in a congenital myasthenic syndrome (CMS) mouse model View project. Biochemical Journal, 450, 265-274. ; Radu, B. M., Osculati, A. M. M., Suku, E., Banciu, A., Tsenov, G., Merigo, F., Di Chio, M., Banciu, D. D., Tognoli, C., Kacer, P., & Giorgetti, A. (2017). All muscarinic acetylcholine receptors (M1-M5) are expressed in murine brain microvascular endothelium. Scientific Reports, 7, 1-15. ; Ragozzino, M. E., Artis, S., Singh, A., Twose, T. M., Beck, J. E., & Messer, W. S. (2012). The selective M 1 muscarinic cholinergic agonist CDD-0102A enhances working memory and cognitive flexibility. Journal of Pharmacology and Experimental Therapeutics, 340, 588-594. ; Risacher, S. L., McDonald, B. C., Tallman, E. F., West, J. D., Farlow, M. R., Unverzagt, F. W., Gao, S., Boustani, M., Crane, P. K., Petersen, R. C., & Jack, C. R. (2016). Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurology, 73, 721-732. ; Rudolph, J. L., Salow, M. J., Angelini, M. C., & McGlinchey, R. E. (2008) The anticholinergic risk scale and anticholinergic adverse effects in older persons. Archives of Internal Medicine, 168, 508-513. ; Sarter, M., & Parikh, V. (2005). Choline transporters, cholinergic transmission and cognition. Nature Reviews Neuroscience, 6, 48-56. ; Sato, A., Sato, Y., & Uchida, S. (2004). Activation of the intracerebral cholinergic nerve fibers originating in the basal forebrain increases regional cerebral blood flow in the rat’s cortex and hippocampus. Neuroscience Letters, 361, 90-93. https://doi.org/10.1016/j.neulet.2004.01.004. ; Schmitz, T. W., Mur, M., Aghourian, M., Bedard, M. A., & Spreng, R. N. (2018). Longitudinal Alzheimer’s degeneration reflects the spatial topography of cholinergic basal forebrain projections. Cell Reports, 24, 38-46. https://doi.org/10.1016/j.celrep.2018.06.001. ; Schmitz, T. W., Soreq, H., Poirier, J., & Spreng, R. N. (2020). Longitudinal basal forebrain degeneration interacts with TREM2/C3 biomarkers of inflammation in pre-symptomatic Alzheimer’s disease. Journal of Neuroscience, 40, 1184-1219. ; Sejvar, J. J., Holman, R. C., Bresee, J. S., Kochanek, K. D., & Schonberger, L. B. (2005). Amyotrophic lateral sclerosis mortality in the United States, 1979-2001. Neuroepidemiology, 25, 144-152. https://doi.org/10.1159/000086679. ; Selkoe, D. J. (2001). Alzheimer's disease: Genes, proteins, and therapy. Physiological Reviews, 81(2), 741-766. ; Simón, D., Hernández, F., & Avila, J. (2013) The Involvement of cholinergic neurons in the spreading of tau pathology. Frontiers in Neurology, 4, 74. https://doi.org/10.3389/fneur.2013.00074. ; Sugita, S., Fleming, L. L., Wood, C., Vaughan, S. K., Gomes, M. P. S. M., Camargo, W., Naves, L. A., Prado, V. F., Prado, M. A. M., Guatimosim, C., & Valdez, G. (2016). VAChT overexpression increases acetylcholine at the synaptic cleft and accelerates aging of neuromuscular junctions. Skeletal Muscle, 6, 31. https://doi.org/10.1186/s13395-016-0105-7. ; Takeda, S. (2019). Progression of Alzheimer’s disease, tau propagation, and its modifiable risk factors. Neuroscience Research, 141, 36-42. ; Tune, L., Carr, S., Hoag, E., & Cooper, T. (1992). Anticholinergic effects of drugs commonly prescribed for the elderly: Potential means for assessing risk of delirium. American Journal of Psychiatry, 149, 1393-1394. ; Vinters, H. V., Zarow, C., Borys, E., Whitman, J. D., Tung, S., Ellis, W. G., Zheng, L., & Chui, H. C. (2018). Review: Vascular dementia: clinicopathologic and genetic considerations. Neuropathology and Applied Neurobiology, 44(3), 247-266. https://doi.org/10.1111/nan.12472. ; Wang, J., Zhang, H. Y., & Tang, X. C. (2009). Cholinergic deficiency involved in vascular dementia: Possible mechanism and strategy of treatment. Nature Publishing Group. ; Yamada, M., Lamping, K. G., Duttaroy, A., Zhang, W., Cui, Y., Bymaster, F. P., McKinzie, D. L., Felder, C. C., Deng, C. X., Faraci, F. M., & Wess, J. (2001). Cholinergic dilation of cerebral blood vessels is abolished in M5 muscarinic acetylcholine receptor knockout mice. Proceedings of the National Academy of Sciences of the United States of America, 98, 14096-14101. ; Yldz, N., Akkoç, Y., Erhan, B., Gündüz, B., Ylmaz, B., Alaca, R., Gök, H., Köklü, K., Ersöz, M. U., Çınar, E., & Karapolat, H. A. (2014). Neurogenic bladder in patients with traumatic spinal cord injury: Treatment and follow-up. Spinal Cord, 52, 462-467. ; Yoshiyama, Y., Kojima, A., Itoh, K., Isose, S., Koide, M., Hori, K., & Arai, K. (2015) Does anticholinergic activity affect neuropathology? Implication of neuroinflammation in Alzheimer’s disease. Neurodegenerative Diseases, 15, 140-148. ; Yoshiyama, Y., Kojima, A., Itoh, K., Uchiyama, T., & Arai, K. (2012). Anticholinergics boost the pathological process of neurodegeneration with increased inflammation in a tauopathy mouse model. Neurobiology of Diseases, 45, 329-336. ; Zhu, H., Yan, H., Tang, N., Li, X., Pang, P., Li, H., Chen, W., Guo, Y., Shu, S., Cai, Y., & Pei, L. (2017). Impairments of spatial memory in an Alzheimer’s disease model via degeneration of hippocampal cholinergic synapses. Nature Communications, 8, 1-13.
- Substance Nomenclature: 0 (Cholinergic Antagonists)
- Entry Date(s): Date Created: 20201122 Date Completed: 20211117 Latest Revision: 20211117
- Update Code: 20240513
|
